June 8, 2021 – They’re among a handful of companies seeking to address what they see as a growing problem, particularly with no drugs approved by the U.S. Food and Drug Administration for treatment. According to, 69 studies have been registered for drugs aimed at cannabis use disorder. Of those, around a third appear to be recruiting or enrolling subjects.

Read More: Cannabis Almost as Addictive as Opioids Among Teens, Study Finds

“Cannabis is the most common substance of abuse besides alcohol and tobacco, and there is no FDA-approved drug, which is concerning when you look at where cannabis use in general is headed,” Indivior Chief Executive Officer Mark Crossley said in an interview.

In the U.S. alone, where an increasing number of states have approved marijuana use and there’s growing momentum for federal legalization, the cannabis industry is expected to reach $41.5 billion by 2025, according to figures from New Frontier Data. The National Institute on Drug Abuse cites research suggesting 9% to 30% of people who use marijuana may become addicted.


[ninja-popup ID=12216]